Ra Pharmaceuticals (RARX) Downgraded to “Strong Sell” at ValuEngine

Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Friday.

RARX has been the topic of several other reports. Zacks Investment Research downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Credit Suisse Group upped their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. BMO Capital Markets upped their target price on Ra Pharmaceuticals in a research report on Tuesday, December 5th. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.50.

Shares of Ra Pharmaceuticals (RARX) traded down $0.31 on Friday, hitting $7.02. The stock had a trading volume of 148,204 shares, compared to its average volume of 135,696. Ra Pharmaceuticals has a 12-month low of $6.94 and a 12-month high of $27.84. The stock has a market cap of $158.84, a price-to-earnings ratio of -2.84 and a beta of 2.15.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.06). equities research analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its position in Ra Pharmaceuticals by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after purchasing an additional 2,543 shares during the period. California State Teachers Retirement System grew its position in Ra Pharmaceuticals by 26.1% during the 2nd quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after purchasing an additional 4,300 shares during the period. Goldman Sachs Group Inc. grew its position in Ra Pharmaceuticals by 7.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after purchasing an additional 4,751 shares during the period. New York State Common Retirement Fund grew its position in Ra Pharmaceuticals by 87.8% during the 2nd quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock worth $260,000 after purchasing an additional 6,499 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in Ra Pharmaceuticals by 70.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after purchasing an additional 9,000 shares during the period. 69.59% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/04/ra-pharmaceuticals-rarx-downgraded-to-strong-sell-at-valuengine.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply